Xtl Biopharmaceuticals Ltd Stock Price Prediction
| XTLB Stock | USD 2.44 0.03 1.21% |
Oversold Vs Overbought
73
Oversold | Overbought |
XTL Biopharmaceuticals stock price prediction is an act of determining the future value of XTL Biopharmaceutica shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of XTL Biopharmaceutica's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of XTL Biopharmaceutica and does not consider all of the tangible or intangible factors available from XTL Biopharmaceutica's fundamental data. We analyze noise-free headlines and recent hype associated with XTL Biopharmaceuticals Ltd, which may create opportunities for some arbitrage if properly timed.
Below are the key fundamental drivers impacting XTL Biopharmaceutica's stock price prediction:Quarterly Earnings Growth (0.76) | Wall Street Target Price 30 |
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of XTL Biopharmaceutica based on different types of headlines from major news networks to social media. The XTL stock price prediction module provides an analysis of price elasticity to changes in media outlook on XTL Biopharmaceutica over a specific investment horizon. Using XTL Biopharmaceutica hype-based prediction, you can estimate the value of XTL Biopharmaceuticals Ltd from the perspective of XTL Biopharmaceutica response to recently generated media hype and the effects of current headlines on its competitors.
This module is based on analyzing investor sentiment around taking a position in XTL Biopharmaceutica. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in XTL Biopharmaceutica to buy its stock at a price that has no basis in reality. In that case, they are not buying XTL because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
XTL Biopharmaceutica after-hype prediction price | USD 2.57 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
XTL |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of XTL Biopharmaceutica's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
XTL Biopharmaceutica After-Hype Price Prediction Density Analysis
As far as predicting the price of XTL Biopharmaceutica at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in XTL Biopharmaceutica or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of XTL Biopharmaceutica, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
XTL Biopharmaceutica Estimiated After-Hype Price Volatility
In the context of predicting XTL Biopharmaceutica's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on XTL Biopharmaceutica's historical news coverage. XTL Biopharmaceutica's after-hype downside and upside margins for the prediction period are 0.13 and 20.11, respectively. We have considered XTL Biopharmaceutica's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
XTL Biopharmaceutica is abnormally volatile at this time. Analysis and calculation of next after-hype price of XTL Biopharmaceuticals is based on 3 months time horizon.
XTL Biopharmaceutica Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as XTL Biopharmaceutica is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading XTL Biopharmaceutica backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with XTL Biopharmaceutica, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
2.62 | 17.54 | 0.13 | 0.29 | 9 Events / Month | 4 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
2.44 | 2.57 | 5.33 |
|
XTL Biopharmaceutica Hype Timeline
XTL Biopharmaceuticals is at this time traded for 2.44. The entity has historical hype elasticity of 0.13, and average elasticity to hype of competition of 0.29. XTL is expected to increase in value after the next headline, with the price projected to jump to 2.57 or above. The average volatility of media hype impact on the company the price is over 100%. The price jump on the next news is projected to be 5.33%, whereas the daily expected return is at this time at 2.62%. The volatility of related hype on XTL Biopharmaceutica is about 15660.71%, with the expected price after the next announcement by competition of 2.73. XTL Biopharmaceuticals Ltd currently holds about 5.16 M in cash with (901 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.95. Given the investment horizon of 90 days the next expected press release will be in about 9 days. Check out XTL Biopharmaceutica Basic Forecasting Models to cross-verify your projections.XTL Biopharmaceutica Related Hype Analysis
Having access to credible news sources related to XTL Biopharmaceutica's direct competition is more important than ever and may enhance your ability to predict XTL Biopharmaceutica's future price movements. Getting to know how XTL Biopharmaceutica's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how XTL Biopharmaceutica may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| BNTC | Benitec Biopharma Ltd | (0.19) | 4 per month | 4.08 | 0.19 | 12.45 | (8.41) | 38.29 | |
| XBIO | Xenetic Biosciences | 0.21 | 3 per month | 3.81 | 0.05 | 8.15 | (6.54) | 19.37 | |
| PRPH | ProPhase Labs | 0.57 | 9 per month | 4.57 | 0.04 | 5.74 | (5.77) | 34.01 | |
| BVXV | BiondVax Pharmaceuticals | (0.06) | 5 per month | 0.00 | (0.17) | 4.26 | (7.00) | 26.71 | |
| BOSC | BOS Better Online | 0.03 | 4 per month | 1.41 | 0.03 | 2.88 | (2.82) | 14.35 |
XTL Biopharmaceutica Additional Predictive Modules
Most predictive techniques to examine XTL price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for XTL using various technical indicators. When you analyze XTL charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About XTL Biopharmaceutica Predictive Indicators
The successful prediction of XTL Biopharmaceutica stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as XTL Biopharmaceuticals Ltd, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of XTL Biopharmaceutica based on analysis of XTL Biopharmaceutica hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to XTL Biopharmaceutica's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to XTL Biopharmaceutica's related companies. | 2013 | 2023 | 2024 (projected) | Payables Turnover | 1.63 | 0.45 | 0.47 | Days Of Inventory On Hand | 148.76 | 171.07 | 162.52 |
Story Coverage note for XTL Biopharmaceutica
The number of cover stories for XTL Biopharmaceutica depends on current market conditions and XTL Biopharmaceutica's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that XTL Biopharmaceutica is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about XTL Biopharmaceutica's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
View All Premium Stories
XTL Biopharmaceutica Short Properties
XTL Biopharmaceutica's future price predictability will typically decrease when XTL Biopharmaceutica's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of XTL Biopharmaceuticals Ltd often depends not only on the future outlook of the potential XTL Biopharmaceutica's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. XTL Biopharmaceutica's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 5.4 M | |
| Cash And Short Term Investments | 3.7 M |
Check out XTL Biopharmaceutica Basic Forecasting Models to cross-verify your projections. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for XTL Stock analysis
When running XTL Biopharmaceutica's price analysis, check to measure XTL Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XTL Biopharmaceutica is operating at the current time. Most of XTL Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of XTL Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XTL Biopharmaceutica's price. Additionally, you may evaluate how the addition of XTL Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is XTL Biopharmaceutica's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share (0.40) | Return On Assets (0.13) | Return On Equity (0.62) |
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.